A new study published in BMC Nephrology examined the role of total bilirubin as a potential clinical marker in adults ...

Vitamin B12 deficiency develops slowly but can cause lasting damage if untreated. Warning signs include fatigue, tingling hands or feet, a red tongue and memory issues. Boost your intake with vitamin ...

Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.

Chronic alcohol consumption disrupts the blood-brain barrier, but Faecalibacterium prausnitzii shows promise in repairing ...

Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 millionOperational pilot ...

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing ...

“Some people have no early symptoms, so blood test abnormalities (ALT/AST, bilirubin, INR) after starting a supplement also warrant stopping and evaluation,” adds Rissetto. Of all of the symptoms, ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did ...

In 2024, the U.S. FDA granted HYRNUO Breakthrough Therapy designation for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and ...

Citius Oncology, Inc. ("Citius Oncology") , the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , a late-stage biopharmaceutical company developing and commercializing ...